SEQUOIA-HCMAficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcome: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the SEQUOIA-HCM trial, comparing the outcomes of aficamten versus placebo in patients with … Read More
Blog
STOPDAPT-3 Trial: Prasugrel Monotherapy after PCI
STOPDAPT-3 TrialShort and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-3 Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcomes: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the STOPDAPT-3 trial, comparing the outcomes … Read More
NOTUS Trial: Dupilumab in COPD
NOTUS TRIAL Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation A double-blind, placebo-controlled, randomized trial Objective:To assess the efficacy and safety of dupilumab in patients with moderate to severe COPD and evidence of type 2 inflammation. 935 … Read More
IRONMAN Trial: IV Iron in HF
IRONMAN Trial Effectiveness of Intravenous Iron Treatment Versus Standard Care in Patients With Heart Failure and Iron Deficiency A randomized, open-label, blinded-endpoint trial Objective:To evaluate the safety and efficacy of ferric derisomaltose on cardiovascular outcomes among patients with heart failure … Read More
INTERACT4 Trial: Ambulance care for Stroke
INTERACT4 Trial Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke A multicentre, randomized, open-label trial Objective:To determine the effect of prehospital treatment of elevated systolic blood pressure (SBP) in patients with recent onset of symptoms concerning for acute stroke. 2404 Patients … Read More
GZGI Trial: Orforglipron in Obesity
GZGI TRIAL Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Phase 2, randomized, double-blind, placebo-controlled trial Objective:To assess the efficacy and safety of orforglipron, an oral non-peptide GLP-1 receptor agonist, for weight reduction in adults with obesity, or … Read More
Bridge-TIMI 73a Trial: Olezarsen for Hypertriglyceridemia
Bridge–TIMI 73a Trial Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk A randomized, placebo-controlled, double-blind trial Objective:To assess the efficacy and safety of olezarsen for lowering triglyceride levels in patients with moderate hypertriglyceridemia plus elevated cardiovascular risk and in … Read More
FCS BALANCE: Olezarsen in Familial Chylomicronemia Syndrome
FCS BALANCE Trial Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (FCS) A phase 3, double-blind, placebo-controlled trial Objective:To assess the efficacy and safety of olezarsen (given once every 4 weeks) in reducing fasting triglyceride level in patients with familial chylomicronemia … Read More
DEA-HF Trial: Diuretics Regimen in CHF
The infographic details findings from the DEA-HF study, which was designed to evaluate the efficacy and safety of three different diuretic treatment regimens in patients with ambulatory congested heart failure (CHF). The study was conducted in a prospective, randomized, open-label, … Read More
ASSERT Trial: Odevixibat in Alagille Syndrome
ASSERT Trial Highlights Efficacy of Odevixibat in Alagille Syndrome In a significant stride towards better management of Alagille Syndrome, the ASSERT trial has recently showcased promising results for the ileal bile acid transporter inhibitor, Odevixibat. This phase 3, double-blind, randomized, … Read More